Making Opioid Drugs Less Alluring Congress should act to

New Post Public Reply Private Reply Replies (0) Message Board

Jan 19, 2013 at 2:20 PM

Making Opioid Drugs Less Alluring
Congress should act to continue the manufacture of tamper-resistant pills.
By LYNN WEBSTER
January 13, 2013

New York Mayor Michael Bloomberg announced last week that the city's emergency rooms will begin restricting patients to a three-day supply of opioid painkillers. The move is meant to counter rampant abuse of OxyContin and other drugs, often by addicts who get pills from family members or friends who receive more than they need from doctors. The Centers for Disease Control and Prevention estimates that 15,000 Americans die annually from opioids, either in suicides or accidental overdoses by addicts and non-addicts.

Given that opioids used in prescription drugs are a mainstay of treatment for millions of Americans with moderate-to-severe pain, how can the drugs be made safer? Part of the answer has to do with formulations of the drugs that are designed to slowly release them over eight, 12 or 24 hours. Although an extended release has therapeutic value in many situations, until recently the pills could be crushed, making all of the opioid effective immediately and giving abusers the euphoria they sought.

The positive news is that now there are products with tamper-resistant features that make extended-release medication far more difficult to convert to an immediate, full dose of the drug. It is still early, but preliminary reports show that tamper-resistant opioids are less likely to be abused.

The Food and Drug Administration has already proposed that manufacturers be required to cooperate to educate all of the nation's more than 350,000 physicians on how to reduce the potential abuse and lethality of extended-release opioids.

But there is a major hitch. Just as it appears that industry has made some progress, albeit small, toward safer opioid formulations, patents are ending on drugs with tamper-resistant formulas—specifically Purdue's OxyContin and Endo's Opana. If the FDA and Congress fail to act, generic versions of extended-release drugs in their original formulations—without a tamper-resistance formula—are due to hit the market in early 2013.

If easily abusable formulations are made available again, why should users seeking a high not turn to them? Furthermore, what incentives will spur opioid makers to continue to formulate safer products?

Here is where Congress comes in. The Stop Tampering of Prescription Pills Act would prevent generics from being approved that are copies of older, more abuse-prone formulations. In effect, the Stopp Act would sidestep a Catch-22 that now confounds makers of tamper-resistant, extended-release opioids. When the companies developed the new versions, the manufacturers could not legally claim that the new formulas were tamper-resistant—because they had not yet met rigorous and time-consuming FDA testing requirements to prove that claim. Instead the makers of extended-release oxymorphone and oxycodone products simply replaced earlier versions of the medications with the new tamper-resistant ones.

The FDA's rule that reformulated products cannot carry labeling claims of tamper resistance until they have been on the market long enough to be sufficiently studied—plus a lack of clarity on what scientific standards tamper-resistant products must meet—is what allows generics to argue that their products are equivalent. Consider the possible harmful result when insurance companies and government payers inevitably place generics on a less-expensive tier than brand-name products, ensuring that patients and doctors are forced via pricing to use less-safe medications. The Stopp Act was designed to avoid these sorts of dilemmas, while helping prescribers differentiate the potential safety of the varying formulations.

Some argue that pharmaceutical companies wish only to safeguard their profits in blocking generics from issuing earlier, non-tamper-resistant formulations. Maybe so—but what is the alternative? Allow recreational abuse and addictive behaviors to shift to the "old school" opioids with no attendant responsibility placed on the generic manufacturers?

The makers of certain extended-release opioids have risen to the call for safer formulations. There is wisdom in expecting makers of generics to abide by the same rules of safety.

With the power to relieve pain comes the danger of ending life if medications are improperly consumed or prescribed. Congress has before it a clear path that likely will prevent innumerable deaths. I hope lawmakers will take it.

Dr. Webster is president-elect of the American Academy of Pain Medicine and medical director of CRILifetree in Salt Lake City.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tarte's Record-Breaking Collab: 60 Seconds to Sellout

When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...

Greasezilla to Process 15M Gallons of FOG Yearly

Greasezilla Steps Up for FOG Processing If there’s one thing that makes dealing with wastewater a greasy business, it’s FOG - fats, oils, and grease. It’s the stuff nightmares are made of for any utility trying to keep their pipes clear and their operations running smooth. Now, Greasezilla is stepping into the spotlight at one of the country's largest wastewater...

AbsenceSoft's AI Leave Planner Tackles HR Headaches

Pioneering Technology in Leave Management AbsenceSoft is rolling out a tool that's about to shake up the HR world in a big way. MyAbsence, powered by AbsenceSoftAI, seems ready to cut down on the common confusions that send HR folks spinning around like they're in a two-step dance competition, juggling leave requests and compliance checks. It's all about getting the...

Systemair Wins First Natural Refrigerant Heat Pump Deal

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...

AI Shift: From Tech Marvels to Practical Uses

A New Chapter in the AI Narrative Take a seat, folks, because we're watching AI swing from showy tech to something as plain as plumbing infrastructure. Imagine models that once cost bundles per token now going for peanuts. We're talking a nosedive from $37.50 to a mere 18 cents. It’s a seismic shift, steering the conversation from 'Are they the best models?' to 'How...

Lemon Grove Bans Bird Sales to Combat Cruelty

A Bird's Eye View on Lemon Grove's Bold Stand The folks in Lemon Grove, California, just sent out a loud and clear message: put an end to the inhumane sale of birds in pet stores. With 65% of voters backing Measure E, they've decided that birds fly best when they aren't part of a retail circus. Under this new rule, stores can only put birds up for adoption if they're...

Kaolin Market Surges to $8.89B by 2031: Key Trends

Riding the Kaolin Wave: Industrial Market Expansion You can't miss the sound of kaolin clinking in as it rides the tide of industrial demand. Reports from MarketsandMarkets™ have kaolin's party rocking all the way to a hefty $8.89 billion by 2031, up from $6.19 billion in 2026. With a sensible 7.5% compound annual growth rate (CAGR), this clay’s is aiming for the...

Hormel Foods Sets Stage for Q4 Earnings Call in December

Hormel Foods Prepares for Earnings Spotlight In a world where market instability feels like the only constant, Hormel Foods Corporation (NYSE:HRL) is setting up one of those must-watch moments. You've got DECEMBER 3rd circled on your cal, right? If not, you're about to miss a curtain raiser that could send ripples across portfolios. Setting the Stage: December's Big...

LONGi Achieves 10th BNEF Tier 1 Listing Amidst Stricter Rules

LONGi Surpasses New BNEF Barriers with Ease Alright, let's dig into the meat of the matter today. LONGi has snagged its 10th straight spot in BloombergNEF's (BNEF) Tier 1 list of global energy storage manufacturers. And mind you, that's no small potatoes, especially with stricter financing demands rearing their hefty heads this quarter. Non-Recourse Financing: A Tougher...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...